OR of receiving intravenous tissue plasminogen activator (IV tPA) for patients aged 18–64 years with a primary diagnosis of acute ischaemic stroke, 2010–2013 MarketScan Commercial Claim Inpatient Database (n=39 149)
| OR | 95% CI | |
|---|---|---|
| Age, years | ||
| 18–44 | 1.00 | |
| 45–54 | 0.87* | (0.76 to 0.99) |
| 55–64 | 0.86* | (0.76 to 0.97) |
| Gender | ||
| Female | 1.00 | |
| Male | 1.01 | (0.93 to 1.10) |
| Metropolitan statistical area | ||
| No | 1.00 | |
| Yes | 1.58** | (1.40 to 1.78) |
| Region | ||
| West | 1.00 | |
| Northeast | 0.82** | (0.71 to 0.94) |
| North central | 0.90 | (0.79 to 1.03) |
| South | 0.86* | (0.76 to 0.97) |
| Charlson comorbidity index | ||
| 0–2 | 1.00 | |
| 3–4 | 1.08 | (0.99 to 1.18) |
| 5 or higher | 0.72** | (0.64 to 0.82) |
| Year | ||
| 2010 | 1.00 | |
| 2011 | 1.21** | (1.07 to 1.37) |
| 2012 | 1.26** | (1.12 to 1.42) |
| 2013 | 1.50** | (1.33 to 1.70) |
*Statistical significance at the p<0.05.
**Statistical significance at p<0.01.